vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and COMSCORE, INC. (SCOR). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $93.5M, roughly 1.9× COMSCORE, INC.). COMSCORE, INC. runs the higher net margin — 3.2% vs -0.7%, a 4.0% gap on every dollar of revenue. On growth, AVANOS MEDICAL, INC. posted the faster year-over-year revenue change (0.7% vs -1.5%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $2.9M). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs 3.8%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Comscore, Inc. is an American-based global media measurement and analytics company providing marketing data and analytics to enterprises, advertising agencies, brand marketers, and publishers.
AVNS vs SCOR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $93.5M |
| Net Profit | $-1.3M | $3.0M |
| Gross Margin | 47.5% | 41.0% |
| Operating Margin | 1.4% | 7.0% |
| Net Margin | -0.7% | 3.2% |
| Revenue YoY | 0.7% | -1.5% |
| Net Profit YoY | 99.7% | -3.7% |
| EPS (diluted) | $-0.02 | $9.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $93.5M | ||
| Q3 25 | $177.8M | $88.9M | ||
| Q2 25 | $175.0M | $89.4M | ||
| Q1 25 | $167.5M | $85.7M | ||
| Q4 24 | $179.6M | $94.9M | ||
| Q3 24 | $170.4M | $88.5M | ||
| Q2 24 | $171.7M | $85.8M | ||
| Q1 24 | $166.1M | $86.8M |
| Q4 25 | $-1.3M | $3.0M | ||
| Q3 25 | $-1.4M | $453.0K | ||
| Q2 25 | $-76.8M | $-9.5M | ||
| Q1 25 | $6.6M | $-4.0M | ||
| Q4 24 | $-397.3M | $3.1M | ||
| Q3 24 | $4.3M | $-60.6M | ||
| Q2 24 | $1.8M | $-1.7M | ||
| Q1 24 | $-900.0K | $-1.1M |
| Q4 25 | 47.5% | 41.0% | ||
| Q3 25 | 48.4% | 40.6% | ||
| Q2 25 | 52.6% | 40.6% | ||
| Q1 25 | 53.6% | 39.6% | ||
| Q4 24 | 54.6% | 42.4% | ||
| Q3 24 | 54.5% | 41.2% | ||
| Q2 24 | 55.7% | 39.5% | ||
| Q1 24 | 57.1% | 42.3% |
| Q4 25 | 1.4% | 7.0% | ||
| Q3 25 | 0.1% | 1.9% | ||
| Q2 25 | -42.6% | -1.9% | ||
| Q1 25 | 6.1% | -2.4% | ||
| Q4 24 | -233.0% | 4.1% | ||
| Q3 24 | 7.0% | -67.4% | ||
| Q2 24 | 3.7% | -2.2% | ||
| Q1 24 | 2.4% | -2.2% |
| Q4 25 | -0.7% | 3.2% | ||
| Q3 25 | -0.8% | 0.5% | ||
| Q2 25 | -43.9% | -10.6% | ||
| Q1 25 | 3.9% | -4.7% | ||
| Q4 24 | -221.2% | 3.3% | ||
| Q3 24 | 2.5% | -68.5% | ||
| Q2 24 | 1.0% | -2.0% | ||
| Q1 24 | -0.5% | -1.2% |
| Q4 25 | $-0.02 | $9.50 | ||
| Q3 25 | $-0.03 | $-0.86 | ||
| Q2 25 | $-1.66 | $-2.73 | ||
| Q1 25 | $0.14 | $-1.66 | ||
| Q4 24 | $-8.64 | $-0.47 | ||
| Q3 24 | $0.09 | $-12.79 | ||
| Q2 24 | $0.04 | $-1.19 | ||
| Q1 24 | $-0.02 | $-1.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $23.6M |
| Total DebtLower is stronger | $90.3M | $41.5M |
| Stockholders' EquityBook value | $778.2M | $111.4M |
| Total Assets | $1.1B | $407.7M |
| Debt / EquityLower = less leverage | 0.12× | 0.37× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $23.6M | ||
| Q3 25 | $70.5M | $26.7M | ||
| Q2 25 | $90.3M | $26.0M | ||
| Q1 25 | $97.0M | $31.0M | ||
| Q4 24 | $107.7M | $29.9M | ||
| Q3 24 | $89.0M | $20.0M | ||
| Q2 24 | $92.2M | $14.7M | ||
| Q1 24 | $75.8M | $18.7M |
| Q4 25 | $90.3M | $41.5M | ||
| Q3 25 | $93.4M | $41.4M | ||
| Q2 25 | $95.7M | $41.3M | ||
| Q1 25 | $98.0M | $41.3M | ||
| Q4 24 | $125.3M | $41.2M | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $111.4M | ||
| Q3 25 | $778.0M | $-26.3M | ||
| Q2 25 | $776.3M | $-21.7M | ||
| Q1 25 | $839.4M | $-13.5M | ||
| Q4 24 | $828.5M | $-8.3M | ||
| Q3 24 | $1.2B | $-2.7M | ||
| Q2 24 | $1.2B | $45.8M | ||
| Q1 24 | $1.2B | $51.4M |
| Q4 25 | $1.1B | $407.7M | ||
| Q3 25 | $1.1B | $406.9M | ||
| Q2 25 | $1.0B | $415.9M | ||
| Q1 25 | $1.1B | $421.5M | ||
| Q4 24 | $1.2B | $430.2M | ||
| Q3 24 | $1.7B | $412.5M | ||
| Q2 24 | $1.7B | $474.1M | ||
| Q1 24 | $1.7B | $477.7M |
| Q4 25 | 0.12× | 0.37× | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $3.2M |
| Free Cash FlowOCF − Capex | $21.3M | $2.9M |
| FCF MarginFCF / Revenue | 11.8% | 3.1% |
| Capex IntensityCapex / Revenue | 3.8% | 0.3% |
| Cash ConversionOCF / Net Profit | — | 1.07× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $21.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $3.2M | ||
| Q3 25 | $14.0M | $9.5M | ||
| Q2 25 | $6.8M | $932.0K | ||
| Q1 25 | $25.7M | $9.1M | ||
| Q4 24 | $57.9M | $-10.0M | ||
| Q3 24 | $23.0M | $12.5M | ||
| Q2 24 | $27.8M | $8.7M | ||
| Q1 24 | $-8.0M | $6.9M |
| Q4 25 | $21.3M | $2.9M | ||
| Q3 25 | $7.0M | $9.4M | ||
| Q2 25 | $-4.2M | $787.0K | ||
| Q1 25 | $19.0M | $8.7M | ||
| Q4 24 | $53.1M | $-10.3M | ||
| Q3 24 | $20.0M | $12.4M | ||
| Q2 24 | $21.9M | $8.5M | ||
| Q1 24 | $-12.1M | $6.6M |
| Q4 25 | 11.8% | 3.1% | ||
| Q3 25 | 3.9% | 10.5% | ||
| Q2 25 | -2.4% | 0.9% | ||
| Q1 25 | 11.3% | 10.1% | ||
| Q4 24 | 29.6% | -10.8% | ||
| Q3 24 | 11.7% | 14.0% | ||
| Q2 24 | 12.8% | 10.0% | ||
| Q1 24 | -7.3% | 7.6% |
| Q4 25 | 3.8% | 0.3% | ||
| Q3 25 | 3.9% | 0.1% | ||
| Q2 25 | 6.3% | 0.2% | ||
| Q1 25 | 4.0% | 0.4% | ||
| Q4 24 | 2.7% | 0.2% | ||
| Q3 24 | 1.8% | 0.1% | ||
| Q2 24 | 3.4% | 0.2% | ||
| Q1 24 | 2.5% | 0.3% |
| Q4 25 | — | 1.07× | ||
| Q3 25 | — | 20.96× | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | -3.19× | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
SCOR
| Transferred Over Time | $77.1M | 83% |
| Research Insight Solutions | $14.6M | 16% |
| Related Party | $2.5M | 3% |
